Month: March 2018
Scott Gottlieb, commissioner of the Food and Drug Administration (FDA), on Wednesday criticized what he called a “rigged” system that keeps some generic drugs off the market and leaves patients paying high costs.
A White House advisory panel on Tuesday called for urgent action to address the rising cost of cancer drugs.
In the not-too-distant future, your health insurance, your prescription drugs and some of your treatment may come from the same company.
Antonio Villaraigosa on Monday challenged his top rival in the governor’s race, Lt. Gov. Gavin Newsom, to a one-on-one debate over the viability of a state-sponsored single-payer healthcare system in California.
Without the threat of a tax penalty, one in five Californians would not have signed up for health insurance this year, Harvard University researchers discovered as a part of a survey released Thursday.
In the wake of the federal government’s November, 2017 decision to eliminate the individual mandate to buy health insurance effective in January, 2019, the California Association of Health Plans is urging state leaders to enact a state-based individual mandate as a way to stabilize California’s health care marketplace and protect the significant gains California has made under the
Health and Human Services Secretary Alex Azar said Monday that value-based healthcare "needs to accelerate dramatically" in the U.S., calling for a range of changes to the healthcare system that he said would provide more tools to give consumers more control over their care.
The pharmacy giant issued $40 billion of investment-grade debt in a nine-part offering, people with knowledge of the matter said. That’s surpassed only by Verizon Communication Inc.’s $49 billion offering in 2013 and Anheuser-Busch InBev SA’s $46 billion sale two years ago.
Speaking at the Federation of American Hospitals convention in D.C.,Health and Human Services (HHS) Secretary Alex Azar laid out a series of actions the administration will take that are aimed at lowering health care costs, and warned that it wouldn’t be deterred by powerful special interests.
As policymakers and the administration focus on high drug prices, the brand drugmaker lobby has responded by unleashing millions of dollars in an attempt to shift blame.